SERD Strategy Lab: A Blueprint for Pharmacist-Led Implementation of Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Program Description:

As the treatment landscape for hormone receptor–positive (HR+)/HER2– metastatic breast cancer grows more complex, clinicians still face questions about what to do after a patient progresses on a cyclin-dependent kinase 4/6 inhibitor. Sequencing decisions, molecular testing strategies, and toxicity management vary widely from one institution to the next, often shaped more by practice culture and clinician familiarity than by consistent, evidence-based pathways. Oral selective endocrine receptor degraders (SERDs) are emerging as a critical option in this setting, providing a mechanistically distinct treatment option for appropriately selected patients. However, their safe and effective use depends on interpreting complex biomarker data, navigating payer and testing workflows, and managing a distinct set of toxicities. Oncology and specialty pharmacists sit at the center of these decisions, with responsibilities to interpret ESR1 and comutation results, assess therapy options, and support patients in safe medication use. This activity equips pharmacists to meet these responsibilities through an in-person workshop featuring case-based, small-group problem-solving on sequencing, testing, and toxicity management. Participants will discuss real-world challenges and come away with practical frameworks and ready-to-use tools to apply within their own institutions to anticipate patient barriers and maintain patients on continuous treatment with SERD-based regimens.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: December 2, 2026
Expiration date: February 2, 2027
Time to complete activity: 1 hour
Learner level: Intermediate, Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine evidence-based approaches to position, select, and sequence oral selective estrogen receptor degraders (SERDs) and SERD-based combinations within the hormone receptor-positive (HR+)/HER2– metastatic breast cancer treatment continuum, incorporating endocrine sensitivity, prior therapy/tolerability, comorbidities, and patient preferences
• Apply ESR1, co-mutation, and circulating tumor DNA testing principles to determine when testing is appropriate, interpret results in the context of clinical utility, and operationalize pharmacist-led workflows that support timely, feasible, and payer-aligned use of oral SERDs in HR+/HER2– metastatic breast cancer
• Apply monitoring, supportive care, and adherence strategies to prevent, detect, and manage ocular, metabolic, hematologic, and gastrointestinal toxicities of oral SERDs and SERD-based combinations

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-276-L01-P. The activity is available for CE credit through February 2, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosure

Danielle Roman, PharmD, BCOP, FHOPA,​ has the following relevant financial relationships with ineligible companies to disclose

Consultant: Daiichi Sankyo, Genentech, Pfizer, Regeneron

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Adam Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; and Brianna Winters have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms